Ascentage Pharma H1 2026: Revenue Climbs 29% to $44.5M, Loss Widens to $120.4M
AAPG is trading near its 52-week low of $16.36 (11% above the low) on elevated volume (2.0× avg).
Summary
H1 2026 revenue grew 29% to $44.5M, but net loss widened to $120.4M as R&D and commercial spending accelerated. Cash fell 23% to $279.4M.
Key Events · Earnings and Guidance · AAPG
-
Revenue Up 29% to $44.5M
H1 2026 revenue reached US$44.5 million, up 29.3% year-over-year, driven by product sales growth of 32.6% to US$41.6 million.
-
Net Loss Widens to $120.4M
Net loss increased to US$120.4 million from US$82.5 million in H1 2025, as R&D expenses rose 32% to US$102.8 million and selling expenses rose 64% to US$33.4 million.
-
Cash Position Declines 23%
Cash and bank balances fell to US$279.4 million as of June 30, 2026, down from US$353.2 million at year-end 2025, reflecting accelerated clinical trial spending.
-
Nine Registrational Phase III Trials
The company is advancing nine registrational Phase III trials globally, including four cleared by FDA and EMA, across Olverembatinib and Lisaftoclax programs.
Analysis · AAPG · Life Sciences
First-half 2026 results show strong commercial traction, with revenue up 29% to $44.5 million on product sales growth. Yet the net loss widened to $120.4 million from $82.5 million a year earlier, as R&D and selling expenses surged to support global clinical trials and Lisaftoclax commercialization. Cash declined 23% to $279.4 million, reflecting heavy investment in nine registrational Phase III trials. The dual-engine strategy is gaining momentum, but the widening loss and cash burn are key concerns for investors.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AAPG was trading at $18.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $16.36 to $48.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.